KRAS ARMS results

KRAS ARMS result

PGM sequencing

PGM sequencing for assay sensitivit

Sanger sequencing

Sanger sequencing for Assay sensitivit

Additional file 1: Figure S1. of Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma

AREG RNA and protein levels in pancreatic cancer cells and pancreatic stellate cells. A, AREG mRNA levels in pancreatic cancer cells and pancreatic stellate cells. B, AREG protein levels in pancreatic cancer cells and pancreatic stellate cells, * indicates a P < 0.05. (DOC 718 kb

Representative PDAC cases with different EGFR/CXCR4 expression profiles: EGFR-/CXCR4− (A), EGFR+/CXCR4− (B), EGFR-/CXCR4+ (C), and EGFR+/CXCR4+ (D). Magnification x 100.

<p>Representative PDAC cases with different EGFR/CXCR4 expression profiles: EGFR-/CXCR4− (A), EGFR+/CXCR4− (B), EGFR-/CXCR4+ (C), and EGFR+/CXCR4+ (D). Magnification x 100.</p

Summary of baseline patient characteristics (n = 131).

<p>Summary of baseline patient characteristics (n = 131).</p

Univariate analysis for disease-free survival and overall survival.

<p>Univariate analysis for disease-free survival and overall survival.</p

Multivariate analysis for disease-free survival and overall survival.

<p>Multivariate analysis for disease-free survival and overall survival.</p

Representative PDAC cases with different EGFR/CXCR4 expression profiles: EGFR-/CXCR4− (A), EGFR+/CXCR4− (B), EGFR-/CXCR4+ (C), and EGFR+/CXCR4+ (D). Magnification x 100.

<p>Representative PDAC cases with different EGFR/CXCR4 expression profiles: EGFR-/CXCR4− (A), EGFR+/CXCR4− (B), EGFR-/CXCR4+ (C), and EGFR+/CXCR4+ (D). Magnification x 100.</p

Overall survival of the 23 PMEC patients with follow-up.

<p>(A) OS according to age. (B) OS according to growth pattern. (C) OS according to tumor diameter. (D) OS according to tumor grade. (E) OS according to Ki-67 labeling index. (F) OS according to surgical resection.</p